Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00

Nautilus Biotechnology (NASDAQ:NAUT) had its price objective boosted by Guggenheim from $2.50 to $4.00 in a research note published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also weighed in on NAUT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Thursday, January 22nd. Wall Street Zen upgraded Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.00.

Nautilus Biotechnology Price Performance

Shares of NASDAQ:NAUT opened at $2.42 on Friday. The business’s 50 day moving average price is $2.16 and its 200-day moving average price is $1.59. Nautilus Biotechnology has a 1 year low of $0.62 and a 1 year high of $3.08. The firm has a market capitalization of $306.28 million, a price-to-earnings ratio of -5.15 and a beta of 1.44.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. On average, sell-side analysts expect that Nautilus Biotechnology will post -0.57 earnings per share for the current year.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of institutional investors have recently added to or reduced their stakes in NAUT. Garde Capital Inc. acquired a new position in Nautilus Biotechnology during the fourth quarter worth $35,000. Hudson Bay Capital Management LP purchased a new position in shares of Nautilus Biotechnology during the 4th quarter worth $37,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Nautilus Biotechnology during the 3rd quarter valued at about $38,000. Qube Research & Technologies Ltd purchased a new stake in shares of Nautilus Biotechnology in the second quarter valued at about $45,000. Finally, Virtu Financial LLC increased its position in Nautilus Biotechnology by 19.6% during the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after purchasing an additional 3,849 shares during the last quarter. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Trending Headlines about Nautilus Biotechnology

Here are the key news stories impacting Nautilus Biotechnology this week:

• Positive Sentiment: Guggenheim raised its price target to $4.00 from $2.50 and initiated/maintained a “buy” rating, implying ~65% upside from the recent price — this analyst action likely supported buying interest. Guggenheim price-target raise
• Positive Sentiment: Q4 2025 results beat expectations on the bottom line: Nautilus reported EPS of ($0.11) vs. consensus ($0.14), and management highlighted strategic progress on its platform and early-access customers — the beat and commentary support a constructive near-term outlook. Earnings release and call
• Neutral Sentiment: Management’s earnings call and published transcripts emphasized “strategic advances” and commercial progress (early-access program ramp), which are positive developments but still early-stage—impact depends on successful scale-up and conversion to sustained revenue. Earnings call transcript
• Negative Sentiment: Nautilus guided to 15%–20% expense growth in 2026 as it scales the early-access program — higher operating spend will widen losses near-term and raises execution risk if commercialization or customer uptake lags expectations. Expense guidance article

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.